Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients
Transplant International · 2023
DOI: 10.3389/ti.2023.10816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2023. Verfasst von Christophe Masset und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie Clinique, CHU Nantes, Nantes, France. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Kidney Transplantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The choice between Basiliximab (BSX) or Anti-Thymocyte Globulin (ATG) as induction therapy in non-immunized kidney transplant recipients remains uncertain. Whilst ATG may allow steroid withdrawal and a decrease in tacrolimus, it also increases infectious complications. We investigated outcomes in non-immunized patients receiving a very low dosage of ATG versus BSX as induction. Study outcomes were patient/graft survival, cumulative probabilities of biopsy proven acute rejection (BPAR), infectious episode including CMV and post-transplant diabetes (PTD). Cox, logistic or linear statistical models were used depending on the studied outcome and models were weighted on propensity scores. 100 patients received ATG (mean total dose of 2.0 mg/kg) and 83 received BSX. Maintenance therapy was comparable. Patient and graft survival did not differ between groups, nor did infectious complications. There was a trend for a higher occurrence of a first BPAR in the BSX group (HR at 1.92; 95%CI: [0.77; 4.78]; p = 0.15) with a significantly higher BPAR episodes (17% vs 7.3%, p = 0.01). PTD occurrence was significantly higher in the BSX group (HR at 2.44; 95%CI: [1.09; 5.46]; p = 0.03). Induction with a very low dose of ATG in non-immunized recipients was safe and associated with a lower rate of BPAR and PTD without increasing infectious complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie Clinique, CHU Nantes, Nantes, France.
- INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Université, Nantes, France.
- Etablissement Francais du Sang, HLA Laboratory, Loos Nantes, France.
Zitieren
APA
Masset, C., Kerleau, C., Blancho, G., Hourmant, M., Walencik, A., Ville, S., Kervella, D., Cantarovich, D., Houzet, A., Giral, M., Garandeau, C., Dantal, J., & Nantes DIVAT Consortium (2023). Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients. Transplant International. https://doi.org/10.3389/ti.2023.10816
Vancouver
Masset C, Kerleau C, Blancho G, Hourmant M, Walencik A, Ville S, et al. Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients. Transplant International. 2023. doi:10.3389/ti.2023.10816
BibTeX
@article{Masset2023,
author = {Masset, Christophe and Kerleau, Clarisse and Blancho, Gilles and Hourmant, Maryvonne and Walencik, Alexandre and Ville, Simon and Kervella, Delphine and Cantarovich, Diego and Houzet, Aurélie and Giral, Magali and Garandeau, Claire and Dantal, Jacques and Nantes DIVAT Consortium, Nantes DIVAT Consortium},
title = {Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients},
journal = {Transplant International},
year = {2023},
doi = {10.3389/ti.2023.10816}
}
EUVIMED